Poor quality medicine is one of the obstacles to improving health in developing countries. One in 10 medicines may not meet acceptable standards, according to the World Health Organisation (WHO).
New Delhi: Pharmaceutical companies that market medicines made by third parties in the country will now be held responsible for drug product quality with the health and family welfare ministry on Thursday issuing a notification to this effect. The move will impact many big domestic and multinational pharmaceutical companies that get their medicines manufactured by smaller companies.
An new app that detects counterfeit medical products on sale in the UAE is about to be launched. Officials said the programme would allow users to identify if drugs were legitimate by scanning the barcode displayed on packaging. The move comes as the growth of the counterfeit drug market continues to increase exponentially.
When my beloved Uncle Vincent developed liver cancer three years ago, it became a race against time to get the drugs he needed to stop the disease from spreading. After a long and desperate search we finally tracked them down — more than 4,000 miles away.
We hope you had a restful holiday season and are settling into the new year! Coming off the heels of a successful 2019, we’re excited to make 2020 the Medicines We Can Trust campaign’s most ambitious year yet.
Poor access to health care has made several African countries attractive for falsified and substandard drugs. Seven countries have responded with a new initiative. Paul Adepoju reports.
DAVOS, Switzerland—The key to building resilient health care systems around the world is rebuilding trust in health care. That was one of the fundamental points made in a fascinating panel discussion I moderated this morning on the first official day of programming here at the 50th annual meeting of the World Economic Forum.
KINGSTON, Jamaica — Sydonna Tugwell, a laboratory technologist at the Medicines Quality Control and Surveillance Department of the Caribbean Public Health Agency, or CARPHA, arrives for work each day at an inconspicuous building in Kingston’s Hope Gardens. Outside, the botanical surroundings are filled with birdsong and the city’s traffic is down to a dull hum. Perhaps surprisingly, it is in this tranquil setting that Tugwell and seven other colleagues are playing a crucial role in transforming the region’s health care system.
Substandard and falsified medical products (including medicines, vaccines, biologics, and diagnostics1) represent a significant and growing threat to human health. Substandard medical products result from errors, corruption, negligence, or poor practice in manufacturing, procurement, regulation, transportation, or storage. By contrast, falsified products result from criminal fraud. Although substandard and falsified medical products have been traded for many centuries, in the last few decades the problem has grown with the increased complexity of the global pharmaceutical economy and internet sales.
In September 2015, I joined more than 190 world leaders at the UN General Assembly in New York, where we renewed the global commitment to fight poverty by launching the Sustainable Development Goals. Together, we took the pledge to work hard to ensure that the 7.5bn citizens of the world live in dignity, with improved health and education.